Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications

Seminars in Diagnostic Pathology

Volumn 25, Issue 4, 2008, Pages 232-244

  Lopez Beltran, Antonio ^a   Kirkali, Ziya ^b   Cheng, Liang ^c   Egevad, Lars ^d   Regueiro, Juan C ^e   Blanca, Ana ^e   Montironi, Rodolfo ^f  

^a Universidad de Cordoba   (Spain)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bladder cancer; Pathology; Prostate cancer; Renal cancer; Targeted therapy

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATRASENTAN; AXITINIB; BEVACIZUMAB; CANCER ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; IMATINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MGC 0103; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PAZOPANIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE FUSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR MECHANICS; MONOTHERAPY; ONCOGENE; ONCOGENE NEU; PAPILLARY CARCINOMA; PATHOLOGIST; PATHOLOGY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; UROLOGIC NEOPLASMS;

EID: 53749086992     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.07.006     Document Type: Article

References (111)

1. Cross S. The molecular pathology of new anti-cancer agents. Curr Diagn Pathol 11 (2005) 329-339
2. Lam J.S., Leppert J.T., Belldegrun A.S., et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23 (2005) 202-212
3. Lam J.S., Leppert J.T., Figlin R.A., et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66 (2005) 1-9
4. Ladanyi M. Targeted therapy of cancer: new roles for pathologists. Mod Pathol 21 suppl 2 (2008) S1
5. Lam J.S., Yamashiro J., Shintaku I.P., et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 11 (2005) 2591-2596
6. Leppert J.T., Lam J.S., Pantuck A.J., et al. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 96 (2005) 281-285
7. Lexander H., Franzen B., Hirschberg D., et al. Differential protein expression in anatomical zones of the prostate. Proteomics 5 (2005) 2570-2576
8. Lexander H., Palmberg C., Auer G., et al. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 27 (2005) 263-272
9. Lexander H., Palmberg C., Hellman U., et al. Correlation of protein expression. Gleason score and DNA ploidy in prostate cancer. Proteomics 6 (2006) 4370-4380
10. Agarwal P.K., Black P.C., McConkey D.J., et al. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs 12 (2007) 435-448
11. Barbisan F., Santinelli A., Mazzucchelli R., et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 112 (2008) 636-644
12. Barry M., Perner S., Demichelis F., et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70 (2007) 630-633
13. Billerey C., Chopin D., Aubriot-Lorton M.H., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158 (2001) 1955-1959
14. Biroccio A., D'Angelo C., Jansen B., et al. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. J Cell Physiol 204 (2005) 463-469
15. Black P.C., Agarwal P.K., and Dinney C.P. Targeted therapies in bladder cancer: an update. Urol Oncol 25 (2007) 433-438
16. Black P.C., and Dinney C.P. Bladder cancer angiogenesis and metastasis: translation from murine model to clinical trial. Cancer Metastasis Rev 26 (2007) 623-634
17. Blehm K.N., Spiess P.E., Bondaruk J.E., et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12 (2006) 4671-4677
18. Bono A.V., Mazzucchelli R., Ferrari I., et al. Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. J Clin Pathol 60 (2007) 443-446
19. Bradley D.A., Dunn R., Nanus D., et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 5 (2007) 460-463
20. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 (2007) 4536-4541
21. Carducci M.A., and Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12 (2006) 6296s-6300s
22. Carducci M.A., Padley R.J., Breul J., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679-689
23. Lopez Beltran A., Cheng L., Mazzucchelli R., et al. Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res (2008) (in press)
24. Lopez-Beltran A., Alvarez-Kindelan J., Luque R., et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 215 (2008) 263-272
25. Lopez-Beltran A., Maclennan G.T., de la Haba-Rodriguez J., et al. Research advances in apoptosis-mediated cancer therapy: a review. Anal Quant Cytol Histol 29 (2007) 71-78
26. Lopez-Knowles E., Hernandez S., Kogevinas M., et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12 (2006) 6029-6036
27. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66 (2006) 7401-7404
28. Demichelis F., Fall K., Perner S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
29. Demichelis F., and Rubin M.A. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 60 (2007) 1185-1186
30. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
31. Escudier B., Lassau N., Angevin E., et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13 (2007) 1801-1809
32. Filosa A., and Fabiani A. Angiogenesis and molecular markers as specific therapeutic tragets in renal cell cancer. Anal Quant Cytol Histol 30 (2008) 185-186
33. Gandour-Edwards R., Lara Jr. P.N., Folkins A.K., et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95 (2002) 1009-1015
34. Glaessgen A., Jonmarker S., Lindberg A., et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS (2008) (in press)
35. Gleave M., and Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 23 (2005) 38-46
36. Gleave M., Miyake H., and Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 56 suppl 1 (2005) 47-57
37. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
38. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
39. Haas N.B., and Uzzo R.G. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol 8 (2007) 211-226
40. Haas N.B., and Uzzo R.G. Targeted therapies for kidney cancer in urologic practice. Urol Oncol 25 (2007) 420-432
41. Hadaschik B.A., and Gleave M.E. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25 (2007) 413-419
42. Hadaschik B.A., Sowery R.D., and Gleave M.E. Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 17 (2007) 182-187
43. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
44. Hieronymus H., Lamb J., Ross K.N., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006) 321-330
45. Hofer M.D., Fecko A., Shen R., et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6 (2004) 503-512
46. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
47. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
48. Cheng L., Bishop E., Zhou H., et al. Lymphatic vessel density in radical prostatectomy specimens. Hum Pathol 39 (2008) 610-615
49. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
50. Cornford P.A., Dodson A.R., Parsons K.F., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60 (2000) 7099-7105
51. Jimenez R.E., Hussain M., Bianco Jr. F.J., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7 (2001) 2440-2447
52. Kassouf W., Luongo T., Brown G., et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176 (2006) 787-792
53. Kim S.J., Uehara H., Yazici S., et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98 (2006) 783-793
54. L'Hote C.G., and Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304 (2005) 417-431
55. Lin A.M., Rini B.I., Weinberg V., et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98 (2006) 763-769
56. Linehan W.M. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol 170 (2003) 593-594
57. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
58. Mamane Y., Petroulakis E., LeBacquer O., et al. mTOR, translation initiation and cancer. Oncogene 25 (2006) 6416-6422
59. Marks R.A., Zhang S., Montironi R., et al. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate 68 (2008) 919-923
60. Mehra R., Tomlins S.A., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
61. Mellon K., Wright C., Kelly P., et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153 (1995) 919-925
62. Miyake H., Hara I., and Gleave M.E. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol 12 (2005) 785-794
63. Miyake H., Hara I., Yamanaka K., et al. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep 13 (2005) 341-345
64. Montironi R., Mazzucchelli R., Barbisan F., et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol 52 (2007) 1682-1689
65. Montironi R., Mazzucchelli R., Lopez-Beltran A., et al. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 4 (2007) 321-332
66. Moon C., Park J.C., Chae Y.K., et al. Current status of experimental therapeutics for prostate cancer. Cancer Lett 266 (2008) 116-134
67. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
68. Motzer R.J., and Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 370 (2007) 2071-2073
69. Motzer R.J., and Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 5601-5608
70. Motzer R.J., Hudes G.R., Curti B.D., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25 (2007) 3958-3964
71. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
72. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
73. Motzer R.J., Michaelson M.D., Rosenberg J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178 (2007) 1883-1887
74. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
75. Nelson J., Bagnato A., Battistini B., et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3 (2003) 110-116
76. Nelson J.B. Endothelin inhibition: novel therapy for prostate cancer. J Urol 170 (2003) S65-S67
77. Nelson J.B., Nabulsi A.A., Vogelzang N.J., et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169 (2003) 1143-1149
78. Patard J.J., Pouessel D., Bensalah K., et al. Targeted therapy in renal cell carcinoma. World J Urol 26 (2008) 135-140
79. Patel P.H., Chadalavada R.S., Chaganti R.S., et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12 (2006) 7215-7220
80. Rubin M.A. Targeted therapy of cancer: new roles for pathologists-prostate cancer. Mod Pathol 21 suppl 2 (2008) S44-S55
81. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
82. Paterson J.L., Li Z., Wen X.Y., et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 124 (2004) 595-603
83. Perner S., Mosquera J.M., Demichelis F., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31 (2007) 882-888
84. Petroulakis E., Mamane Y., Le Bacquer O., et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94 (2006) 195-199
85. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
86. Rocchi P., Beraldi E., Ettinger S., et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65 (2005) 11083-11093
87. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64 (2004) 6595-6602
88. Ronnen E.A., Kondagunta G.V., Ishill N., et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107 (2006) 2617-2621
89. Rosenblatt R., Valdman A., Cheng L., et al. Endothelin-1 expression in prostate cancer and high-grade PIN. Anal Quant Cytol Histol (2008) (in press)
90. Sakamoto S., Ryan A.J., and Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 103 (2008) 691-708
91. Santinelli A., Mazzucchelli R., Barbisan F., et al. α-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 128 (2007) 657-666
92. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
93. Shariat S.F., Kattan M.W., Traxel E., et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10 (2004) 1992-1999
94. Shariat S.F., Khoddami S.M., Saboorian H., et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 171 (2004) 1122-1127
95. So A., Gleave M., Hurtado-Col A., et al. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23 (2005) 1-9
96. So A., Rocchi P., and Gleave M. Antisense oligonucleotide therapy in the management of bladder cancer. Curr Opin Urol 15 (2005) 320-327
97. Tickoo S.K., Alden D., Olgac S., et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 177 (2007) 1258-1263
98. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2008) 177-188
99. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
100. Tomlinson D.C., Baldo O., Harnden P., et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213 (2007) 91-98
101. Tomlinson D.C., Hurst C.D., and Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26 (2007) 5889-5899
102. Tomlinson D.C., L'Hote C.G., Kennedy W., et al. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65 (2005) 10441-10449
103. van Rhijn B.W., Lurkin I., Radvanyi F., et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
104. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 10 (1993) 302-313
105. Weidner N., Carroll P.R., Flax J., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
106. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
107. Yamanaka K., Gleave M.E., Hara I., et al. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 4 (2005) 187-195
108. Yamanaka K., Rocchi P., Miyake H., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4 (2005) 1689-1698
109. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
110. Pan C.X., Yang X.J., Lopez-Beltran A., et al. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 18 (2005) 320-323
111. Wang X., Zhang S., MacLennan G.T., et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 13 (2007) 953-957